Background: The use of androgen deprivation therapy for prostate cancer has been increasing, even in settings for which there is weak or no evidence of effi cacy. This pattern suggests that factors other than the typical patient and tumor characteristics may be driving its use. We assessed the importance of the physician as a determinant of the use of androgen deprivation therapy in prostate cancer in a population-based, retrospective cohort study using the Surveillance, Epidemiology and End-Results -Medicare linked database. Methods: Participants included 61 717 men with incident prostate cancer diagnosed from January 1, 1992, through December 31, 1999, and 1802 urologists providing care to them within 1 year of cancer diagnosis. Multilevel analyses were used to estimate and partition the variance in use of androgen deprivation therapy within 6 months of diagnosis between patient or tumor characteristics and urologist to examine the relative contribution of each component to androgen deprivation therapy. Results: The percentage of the total variance in the use of androgen deprivation therapy attributable to the urologist was consistently higher than that attributable to tumor or patient characteristics. This pattern was most pronounced for patients diagnosed from January 1, 1997, through December 31, 1999, in which 22.56% of the total variance in use of androgen deprivation therapy was attributable to the urologist, 9.71% to tumor characteristics (stage or grade), and 4.29% to patient characteristics (age, ethnicity, socio-economic status, comorbidity, geographic region, or year of diagnosis). Conclusions: Which urologist a patient sees may be more important in determining whether they will receive androgen deprivation therapy than tumor or patient characteristics.
interventions is determined by characteristics of the physician. In other words, the treatment provided depends more on the physician who is treating the patient than on specifi c characteristics of the patient's disease. However, previous studies ( 11 -14 ) that have used multilevel analyses to examine the contribution of the physician to variance in the use of various treatments (i.e., for diabetes or angina) or resources (i.e., hospitalizations or pharmacy expenditures) have found the physician's contribution to be quite small, generally less than 10%.
To assess the importance of the physician as a determinant of the use of androgen deprivation therapy in prostate cancer, we conducted a multilevel analysis in a large population-based retrospective cohort by use of the Surveillance, Epidemiology and End-Results (SEER)-Medicare linked database ( 15 , 16 ) . In particular, we compared the percentage of variance in the use of androgen deprivation therapy that was attributable to patient characteristics with the percentage that was attributable to the physician. Although we acknowledge the diffi culties in defi ning appropriate care, we divided the prostate cancer patients into those for whom androgen deprivation therapy was evidence based (i.e., clinical trials showing survival benefi t or improvements in palliation) and those for whom the benefi t of androgen deprivation therapy was uncertain (i.e., no clinical trials showing survival benefi t, or presence of confl icting data regarding benefi ts in the literature). We tested the hypothesis that most of the variance in the use of androgen deprivation therapy was attributable to the physician. We also tested the hypothesis that the variance attributable to the physician would be greater for situations in which the benefi ts of androgen deprivation therapy were uncertain.
66 years old at the time of diagnosis (118 446 subjects). To ensure complete information, patients who were not enrolled in both Medicare Part A and Part B for the 12 months before the diagnosis and the fi rst 6 months after their cancer diagnosis (12 466 cases), were members of a health maintenance organization (24 441 cases), or were diagnosed by autopsy or from a death certifi cate (1474 cases) were excluded, leaving 80 065 eligible patients.
All physicians providing care to the patients within the fi rst year of diagnosis were identifi ed through use of encrypted Unique Physician Identifi er Numbers on Medicare physician claims. For each physician, Medicare claims also contain a two-digit specialty code (e.g., for urology or general surgery), which was reported when the claim was submitted ( 17 ) . From preliminary analyses of Medicare specialty codes of physicians caring for eligible prostate cancer patients, 92.1% of patients were seen by at least one urologist in the year after cancer diagnosis. Moreover, among the 23 642 prostate cancer patients who received androgen deprivation therapy, therapy for 22 304 (94.3%) was administered by a urologist. All physician-level analyses in this study, therefore, used data from urologists only.
We excluded patients who did not see at least one provider identifi ed by Medicare specialty code as an urologist in the year after diagnosis on at least two different days (10 498 patients) or who saw urologists who did not have an assigned Unique Physician Identifi er Number in the claims information (827 patients). When patients were seen by two or more urologists, the patient was assigned to the urologist with 75% or more of the urologist visits in the fi rst year after diagnosis. If a patient did not visit one urologist at least 75% of the time, that patient was excluded (7023 patients), which left a total of 61 717 patients for the study. A total of 1802 urologists were identifi ed as providing care within 1 year of cancer diagnosis to these patients.
Because substantial time trends in use of androgen deprivation therapy were identifi ed over the study period, for some analyses, patients were divided into groups by the period of diagnosis, from 1992 through 1996 and from 1997 through 1999. Patients were also divided into those for whom use of androgen deprivation therapy was defi ned as evidence based (i.e., the evidence-based group) and those for whom its use was defi ned as uncertain (i.e., the uncertain-benefi t group) by use of evidence in the medical literature and on published clinical practice guidelines from the National Comprehensive Cancer Network ( 5 , 18 , 19 ) . Analyses of data from the evidence-based and uncertain-benefi t groups were limited to the period from 1997 through 1999, because the literature supporting use of androgen deprivation therapy as adjuvant therapy with radiation therapy was fi rst published in 1997 ( 20 , 21 ) . The evidence -based group included patients receiving radiation therapy who have T3 tumors (regardless of grade) or who have T2 (confi ned to prostate) tumors with high-grade histology (Gleason score of 8 -10) . The uncertain-benefi t group included all other patients.
Defi nitions of Variables
Patient demographic and tumor characteristics were derived from the SEER records in the linked database and used to categorize patients by age, ethnicity, SEER region of residence at the time of diagnosis, year of diagnosis, clinical stage (T1 through T4), and grade (well differentiated, Gleason score of 2 -4; moderately differentiated, Gleason score of 5 -7; poorly or undifferentiated/ unknown, Gleason score of 8 -10) ( 22 , 23 ) . The American Joint Committee on Cancer staging system was not used because more than 40% of the patients in the SEER database were listed as in the unknown stage within this classifi cation system (reanalysis of the data using the American Joint Committee on Cancer classifi cation for patients with a known stage did not substantially alter the results).
The socioeconomic characteristics of each patient were based on the percentage of adults with fewer than 12 years of education and the percentage of residents living below the poverty level from census tract data. Comorbidity was measured with an adaptation of the Charlson Comorbidity Index ( 24 ) that was developed for use with Medicare physician claims data ( 25 ) .
Surgical androgen deprivation therapy, in the form of orchiectomy, was defi ned by the presence of the Current Procedural Terminology codes or International Classifi cation of Diseases, 9th revision, procedure codes in the Medicare claims. Administration of a gonadotropin-releasing hormone agonist was identifi ed through specifi c Medicare claims codes used to designate each dose given of certain specifi c injectable medications, as described previously ( 2 , 26 ) .
The outcome was receipt of androgen deprivation therapy, which was defi ned as the receipt of at least one dose of a gonadotropin-releasing hormone agonist or undergoing orchiectomy in the fi rst 6 months after diagnosis of prostate cancer. Consequently, the study was limited to examining the early use of androgen deprivation therapy, without considering whether patients received androgen deprivation therapy later in their disease.
Statistical Analysis
Differences in the percentage of patients receiving androgen deprivation therapy across strata were evaluated with chi-square statistics. Logistic regression models were estimated by use of androgen deprivation therapy as a dependent variable, and patient characteristics (i.e., age, comorbidity, ethnicity, socioeconomic status, SEER region, and year of diagnosis) and tumor characteristics (i.e., stage and grade) were estimated as independent variables. The percentage of variance in use of androgen deprivation therapy that was attributable to each patient and tumor characteristic was calculated with the generalized coeffi cient of determination (maximum rescaled R 2 ) for unadjusted analyses (in which each characteristic was analyzed independently, without adjustment for other variables) and calculated with the partial generalized coeffi cient of determination for adjusted analyses (in which each characteristic was analyzed with simultaneous adjustment for the other variables) ( 27 ) .
Use of androgen deprivation therapy was further evaluated with multilevel analyses by using hierarchical generalized linear models ( 28 -30 ) . This method is appropriate when there are various levels of data nested within each other. In this study, patients are nested within urologists. A hierarchical generalized linear model approach allows the estimation and partitioning of variance in use of androgen deprivation therapy between the patient and urologist levels.
As a measure of the importance of the urologist effect on individual use of androgen deprivation therapy, we estimated the percentage of the total variance in the use of androgen deprivation therapy attributable to the urologist, which is defi ned for this study as the intraclass correlation coeffi cient (ICC). This value was estimated by use of the threshold model, a previously described method that is appropriate for a binary outcome ( 31 ) . Both " null " models, which do not include any patient or tumor variables, and adjusted models, which include all of these variables, were used.
The ICCs from the null models were very similar to those from the adjusted models and are, therefore, not presented. For the adjusted models, results were calculated in two ways. In the fi rst method, a residual ICC was calculated that represents the percentage of variance attributable to the urologist after adjustment for available patient and tumor variables (the denominator in the calculation of this percentage was composed of the variance attributable to the urologist, after adjustment for available patient and tumor variables, and the variance attributable to error plus unexplained patient and tumor variables). In the second method, the variance was further partitioned into contributions from the urologist and from available patient or tumor characteristics to calculate the percentage of total variance from each component (in this case, the denominator was total variance, which also included the variance attributable to available patient and tumor characteristics). In this way, the relative importance of each component could be examined. For the main analyses, urologists who saw at least one patient with prostate cancer over the study period were included.
Alternate techniques (linearization and simulation) have been described for estimating ICCs; these techniques have the advantage that an underlying continuous distribution does not have to be assumed, unlike the threshold model ( 32 ) . However, no method has yet been described for further partitioning of the variance for these techniques. We therefore calculated residual ICCs by these techniques to compare them with those from the threshold model. Because the SEER geographic region could also be considered a random effect, we also used a three-level model that included geographic region as the third level (with patients and urologists as the fi rst and second levels, respectively). The results for urologistlevel ICCs from this model were essentially unchanged from the two-level models and were therefore not presented.
As another measure of physician variation in use of androgen deprivation therapy, urologist-specifi c rates of administering androgen deprivation therapy were calculated with a hierarchical generalized linear model that was adjusted for patient and tumor characteristics and then plotted by rank, from lowest to highest. This model also accounts for the fact that urologists with a smaller panel of patients have less reliable estimates of rates of androgen deprivation use. For each urologist, the term panel of patients refers to the number of prostate cancer patients that were identifi ed as having been cared for by that urologist (the provided care may or may not have included androgen deprivation) within 1 year of cancer diagnosis. Each urologist-specifi c rate was therefore adjusted toward the mean rate as a factor of the size of the panel of patients. A urologist rate that is based on a large panel of patients will undergo very little adjustment toward the mean rate, whereas a urologist rate that is based on a small panel will have more adjustment. These analyses were limited to urologists who saw at least fi ve patients with prostate cancer during the study period.
Analyses were performed with the software packages SAS version 9.1 (Cary, NC) and Mlwin version 2.02 (London, United Kingdom). All tests of statistical signifi cance were two-sided, and P values of less than .05 were considered statistically signifi cant. characteristics. Androgen deprivation therapy was more commonly administered to older patients, to those with more comorbidities, to those with more advanced-stage or higher-grade disease, and to patients diagnosed in recent years. Receipt of this therapy varied substantially by SEER region.
R ESULTS

Patient and Tumor Characteristics
Percentage of Variance in the Use of Androgen Deprivation Therapy Attributable to Patient and Tumor Characteristics
We investigated the use of androgen deprivation therapy by patient and tumor characteristics with logistic regression models. Table 2 presents the percentage of variance in the use of androgen deprivation therapy that was attributable to each set of
and grade was associated with the highest percentage of variance, at 11.77%. Ethnicity, the combination of census tract education and poverty, and comorbidity contributed minimally, with each associated with less than 1% of the variance in use of androgen deprivation therapy.
Percentage of Variance in Androgen Deprivation Therapy Use Attributable to the Urologist
A total of 1802 urologists were identifi ed as providing care to the patients in this study within the fi rst year of cancer diagnosis. Table 3 presents a multilevel analysis examining the contribution of the urologist to the variance in androgen deprivation therapy use, with models for the overall cohort of patients and also with models stratifi ed by period (1992 -1996 versus 1997 -1999) . For the period from 1997 through 1999, patients were further stratifi ed into evidence-based and uncertain-benefi t groups, because that period followed the publication of trials ( 20 , 21 ) that showed a survival benefi t for locally advanced cancers treated with the combination of androgen deprivation and radiation. For each model, we have presented the results of two analyses. First, we present the residual ICC, which represents the percentage of variance associated with the urologist after adjustment for available patient and tumor characteristics. Second, we present the further partitioned variance, which represents the percentages of total variance associated with the urologist and with selected patient or tumor variables.
For the entire cohort of patients during the period from 1992 through 1999, the residual ICC was 20.63%, with an increase to 26.55% when the analysis was limited to patients from 1997 through 1999. The residual ICCs when patients were divided into evidence-based and uncertain-benefi t groups were 29.09% and 25.48%, respectively.
When the variance was partitioned further to include the percentage of total variance attributable to patient and tumor variables, the percentage of the total variance attributable to the urologist (16.00%) was higher than that attributable to the combination of tumor stage and grade (13.06%). This pattern * Hierarchical generalized linear model with patient age; comorbidity; ethnicity; Surveillance, Epidemiology, and End Results (SEER) region; tumor stage; grade; year of diagnosis; census tract education; and census tract poverty entered as " level 1 " variables and physician identifi ers entered as " level 2 " variables. ICC = intraclass correlation coeffi cient.
† The percentage of variance attributable to the urologist calculated with a threshold model, after simultaneous adjustment of all available patient and tumor characteristics. The denominator for the calculation of the percentage was composed of the variance attributable to the urologist, after adjustment for available patient and tumor characteristics, and the variance attributable to unexplained patient or tumor variables plus error.
‡ The variance was further partitioned using a threshold model so that the percentages of total variance contributed by the urologist, as well as those contributed by patient and tumor variables, are presented. Results are presented as the percentage of total variance attributable to the indicated characteristic. The denominator is total variance, which is composed of the variance attributable to the urologist after adjustment for available patient and tumor characteristics, the variance attributable to available patient and tumor variables, and the variance attributable to unexplained patient or tumor variables plus error.
was especially pronounced in the period from 1997 through 1999, in which the percentage of the total variance attributable to the urologist was 22.56%, that attributable to the combination of tumor stage and grade was 9.71%, and that attributable to patient characteristics was 4.29%. Similar patterns were found in the evidence-based and uncertain-benefi t groups.
In additional analyses, when we limited the analyses to urologists who saw larger numbers of patients with prostate cancer, we found that the ICCs were similar to those obtained with all urologists. For example, the residual ICC was 20.07% when the analysis was limited to urologists who saw at least 50 patients. To determine the potential impact of the data from patients who received only a few doses of gonadotropin-releasing hormone agonist, we repeated the analysis but excluded patients who received one to four doses in the fi rst year. The residual ICC from this analysis was essentially unaffected, at 20.80%. We also calculated residual ICCs by use of different techniques to compare the results with those from the threshold model ( Table 3 ) . These results showed similar trends but somewhat lower ICCs than those from the threshold model. For example, the most conservative estimates for the residual ICCs (using a simulation model) were 14.70%, 21.05%, and 18.78% for the entire cohort, evidence-based, and uncertain-benefi t group of patients, respectively, compared with 20.63%, 29.09%, and 25.48%, respectively, in the threshold model ( Table 3 ) .
Rates of Androgen Deprivation Therapy Use Attributable to the Urologist
As another measure of physician variation in use of androgen deprivation therapy, urologist-specifi c rates of administering androgen deprivation therapy were calculated with a hierarchical generalized linear model, adjusted for patient and tumor characteristics, and plotted by rank, from lowest to highest. The analyses were limited to patients diagnosed with prostate cancer from 1997 through 1999, and plots were generated for patients in the evidence-based group ( Fig. 1 ) and patients in the uncertainbenefi t group ( Fig. 2 ) . For the evidence-based group, 25 (16.3%) of the 153 urologists had a rate of androgen deprivation therapy use that was statistically signifi cantly different (with a cut-off of P <.05) from the mean rate of 71.3%, with 7 (4.6%) of the 153 urologists having a rate above the mean and 18 (11.8%) of them having a rate below the mean. For the uncertain-benefi t group of patients, 191 (23.6%) of the 808 urologists had a rate of androgen deprivation therapy use that was statistically signifi cantly (with a cut-off of P <.05) different from the mean rate of 36.0%, with 123 (15.2%) of the 808 urologists having a rate above the mean and 68 (8.4%) having a rate below the mean.
D ISCUSSION
This study is, to our knowledge, the fi rst to use multilevel analyses to examine the contribution of the urologist to the use of androgen deprivation therapy for prostate cancer. Although most of the variance in use of androgen deprivation therapy in this study was unexplained, approximately 21% was associated with the urologist. More of the variance was attributable to the urologist than to available patient and tumor characteristics. Thus, the urologist who sees a patient may be a more important determinant of whether that patient will receive androgen deprivation Fig. 1 . Rates of androgen deprivation therapy use for 153 individual urologists by rank, from lowest to highest, who cared for patients in the evidence-based group diagnosed with prostate cancer from 1997 through 1999. The rates were calculated by use of hierarchical generalized linear modeling, adjusted for patient and tumor characteristics. This model also accounts for differences in reliability of individual rates resulting from variations in the size of the panel of patients for each urologist. Each urologist-specifi c rate was therefore adjusted toward the mean of the overall rate as a factor of panel size (i.e., a urologist rate that is based on a large panel of patients will result in very little adjustment toward the mean rate, whereas a urologist rate that is based on a small panel will have more adjustment). This analysis was limited to urologists who saw at least fi ve patients. The horizontal line represents the overall mean rate of androgen deprivation. Error bars represent 95% confi dence intervals for the rates of individual urologists. Black error bars represent urologists that have rates statistically signifi cantly ( P value range = <.001 to .045) below the mean rate, dark gray bars represent urologists that have rates statistically signifi cantly above the mean rate ( P value range = .009 to .025), and light gray bars represent rates that are not different from the mean rate.
Fig. 2.
Rates of androgen deprivation therapy use for 808 individual urologists by rank, from lowest to highest, who cared for patients in the uncertain-benefi t group diagnosed with prostate cancer from 1997 through 1999. Rates were calculated by use of hierarchical generalized linear modeling, adjusted for patient and tumor characteristics. This model also accounts for differences in the reliability of individual rates resulting from variations in the size of the panel of patients for each urologist. Each urologist-specifi c rate was therefore adjusted toward the overall rate mean as a factor of panel size (i.e., a urologist rate that is based on a large panel of patients will result in very little adjustment toward the mean rate, whereas a urologist rate that is based on a small panel will have more adjustment). This analysis was limited to urologists who treated at least fi ve patients. The horizontal line represents the overall mean rate of androgen deprivation. Error bars represent 95% confi dence intervals for the rates of individual urologists. Black error bars represent urologists that have rates statistically signifi cantly ( P value range = <.001 to .049) below the mean rate, dark gray bars represent urologists that have rates statistically signifi cantly above the mean rate ( P value range = <.001 to .050), and light gray bars represent rates that are not different from the mean rate.
therapy than the characteristics of the tumor (e.g., stage or grade) or the patient (e.g., age and comorbidity).
With one exception ( 33 ) , previous studies examining the amount of variance in practice behavior attributable to the physician have found the ICCs to be substantially lower than in our study ( 11 -14 ) . The behaviors examined included resource utilization for care of diabetic patients (ICCs = 1% -4%) ( 11 ) , contribution to managed care pharmacy expenses (ICCs = 0.9% -5.3%) ( 13 ) , patient satisfaction (ICCs = 3.3% -6.5%) ( 12 ) , prescription of beta-blockers to patients with angina (ICC = 7.9%) ( 14 ) , and monitoring of digoxin levels (ICC = 24%) ( 33 ) . Given the generally low ICCs, the authors of these studies concluded that efforts directed at changing physician behavior would likely have a small impact on outcomes and that profi ling individual physicians would be unreliable ( 11, 13 ) .
A number of factors may have explained the higher variance in androgen deprivation use attributable to the urologists in our study. One factor is the uncertainty that surrounds use of androgen deprivation therapy for prostate cancer. For instance, in a national survey of urologists about recommended treatment for patients with localized prostate cancer who were older than 70 years (in which more than one response could be selected) ( 34 ) , 74% chose radiation, 48% chose radical prostatectomy, 31% chose androgen deprivation therapy, and 38% chose observation only. Another factor was the broadening of indications for the use of androgen deprivation therapy during the 1990s ( 2 ) . This factor presumably contributed to the increasing variance attributable to the urologist over time and to the decreasing variance attributable to tumor characteristics. However, we found similar ICCs in the evidence-based and uncertain-benefi t groups, suggesting that medical uncertainty was still playing a role in the evidence-based settings or that there were other important factors driving physician decisions to use androgen deprivation therapy. These factors could include fi nancial incentives for the urologist to prescribe gonadotropinreleasing hormone agonists, pressure from patients to prescribe something in the face of a cancer diagnosis, or infl uences from local opinion leaders ( 35 -37 ) . Physicians may differ in their response to these infl uences ( 38 , 39 ) , and these differences may contribute to the variance in use of androgen deprivation therapy.
Use of androgen deprivation therapy in prostate cancer is important to study for several reasons. First, it is a common treatment for a common cancer. There are more than 200 000 new cases of prostate cancer every year, with recent estimates suggesting that more than 80 000 patients will receive androgen deprivation therapy within 6 months of diagnosis ( 2 ) . Second, androgen deprivation therapy in the form of gonadotropin-releasing hormone agonists is very costly, making it the second highest Medicare Part B expenditure, at approximately $1.2 billion in 2003 ( 8 ) . Finally, androgen deprivation therapy is associated with a host of adverse effects, including reduced quality of life, sexual dysfunction, osteoporosis, and fractures ( 7 , 40 ) .
There are several limitations to this study. Because the analyses used information from Medicare claims, the study included only men who were 66 years or older. However, approximately 70% of men with incident prostate cancer are in that age group ( 41 ) , and androgen deprivation therapy is more commonly used for older men ( 2 ) . Another limitation is that we were unable to examine use of androgen deprivation therapy in health maintenance organization settings, in which the patterns of care may differ ( 42 ) . Some of the study exclusions may also limit the generalizability of our results. For instance, we excluded patients who did not see a urologist at all and excluded some patients who received care from several urologists (which may occur in group practices). In addition, we chose to focus on androgen deprivation therapy initiated within 6 months of diagnosis, without accounting for whether therapy was administered later in the treatment of the disease. This choice was based, in part, on the fact that early androgen deprivation therapy is clinically relevant because it is now being used in approximately 40% of patients with incident prostate cancer and is associated with an increased risk of fracture ( 2 , 23 ) . Also, because we only had data on stage and grade of the tumor at the time of diagnosis, examining androgen deprivation therapy beyond the fi rst year may have introduced additional variation due to use for progression of disease, rather than as initial therapy. Most previous studies assessing the amount of variance attributable to the physician examined continuous outcome measures with statistical methods that are not appropriate for a binary outcome, as in our study. However, the optimal statistical approach for binary outcomes has not yet been clarifi ed. We therefore estimated ICCs via several recently described methods ( 32 ) and found that our results were generally consistent across the approaches used. Finally, all potentially relevant variables (e.g., prostate-specifi c antigen levels) were not available in the study dataset. However, it is unlikely that inclusion of additional tumor variables in the analyses would have substantially altered our results, given that adjustment for other important tumor characteristics, such as stage and grade, had little effect on the ICCs.
There are a number of implications from this study. First, the substantial variations in rates of androgen deprivation use between urologists raise concerns about whether the therapy is being used appropriately ( 10 ) . Second, the ICCs in our study suggest that monitoring of the use of androgen deprivation therapy by individual urologists may be feasible. The reliability of physician profi les increases as the number of patients in the physician's panel increases and as the ICC increases ( 43 ) . Generally, a reliability of 0.8 is considered to be acceptable for making decisions about individual physicians on the basis of their profi les ( 11 , 44 ) . With an ICC of 20%, a urologist would need a panel of 16 patients to achieve a reliability of 0.8 [calculation with the SpearmanBrown prophecy formula ( 43 ) ]. This value compares favorably, for instance, with a physician needing a panel of 100 patients with diabetes to reliably assess that individual's use of hospital resources for diabetes ( 11 ) . The substantial variance in use of androgen deprivation therapy attributable to the urologist, independent of patient factors, suggests that interventions at the level of the urologist (e.g., education or change in reimbursement) may be an effective way to modify the use of this therapy for prostate cancer. Finally, the study fi ndings suggest that primary care physicians should carefully consider the choice of urologist for their patients who may have prostate cancer, because the urologist is an important determinant of how such patients will be managed with regards to androgen deprivation therapy.
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